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Abstract
Objective—Adiponectin is produced by adipose cells and is considered an anti-inflammatory 
molecule. In contrast, C-reactive protein has been identified as a hallmark of systemic 
inflammation and used as a risk marker of cardiovascular disease. Of interest was the relationship 
of these two biomarkers to oral health and cardiovascular risk.
Methods—This investigation examined these two molecules in serum and unstimulated whole 
saliva of patients within 48 hrs. of an acute myocardial infarction (AMI) compared to control 
subjects. We hypothesized a differential response in these biomolecules resulting from the heart 
attack that would be affected by both the BMI and oral health characteristics of the individuals.
Results—Significantly lower adiponectin levels were observed in the serum of the AMI patients. 
Serum adiponectin in both groups and salivary adiponectin in AMI patients decreased with 
increasing BMI. Oral health was significantly worse in the AMI patients, and both serum and 
salivary adiponectin were elevated with better oral health in control subjects. Serum CRP levels 
were increased in the AMI patients regardless of their oral health, and both serum and salivary 
CRP were significantly elevated in S-T wave elevated MI patients (STEMI).
Conclusions—These initial data provide evidence relating obesity and oral health to salivary 
and serum analyte levels that occur in association with cardiac events. Relationships have been 
described between cardiovascular (CVD) risk and periodontal disease. Additionally, various 
systemic inflammatory biomarkers appear to reflect both the CVD risk and the extent/severity of 
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periodontitis. Our findings indicated that oral health and obesity contribute to altering levels of 
these salivary and serum analytes in association with cardiac events. The potential that serum 
and/or salivary biomarkers could aid in evaluating CVD risk requires knowledge regarding how 
the oral health of the individual would impact the effectiveness of these biological measures.
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INTRODUCTION
Adiponectin is a circulating plasma protein produced abundantly and specifically by 
adipocytes and is detected at relatively high total levels in the bloodstream of humans that 
regulates the metabolism of lipids and glucose (1–4). Adiponectin is a major adipocyte-
derived protein with anti-inflammatory and anti-atherogenic properties affecting endothelial 
cells, thus appearing to play a protective role in atherosclerosis development and progression 
(5, 6). C-reactive protein (CRP) is released systemically as part of the acute phase response 
to active inflammation including infection, injury, neoplasia, or chronic local inflammatory 
conditions, e.g. arthritis. Elevated CRP levels have been associated with an increased risk of 
heart attack and support the contribution of chronic inflammation to atherosclerotic vascular 
changes and coronary risk (7, 8). Recent findings suggest that elevated CRP may be just as 
important as elevated LDL cholesterol levels in predicting CVD risk, and that high CRP 
levels may identify high-risk patients (9). Thus, CRP could be considered an independent 
marker of cardiovascular risk (10, 11). These two mediators in serum appear to provide 
information regarding anti-inflammatory (e.g. adiponectin) and pro-inflammatory (e.g. CRP) 
responses that could link metabolic syndrome, obesity, diabetes and cardiovascular disease.
Various studies have begun evaluating an array of biomolecules in saliva as a potential 
diagnostic fluid for both oral and systemic diseases (12–14). Numerous reports have 
explored salivary profiles of analytes related to both oral (14–17) and systemic diseases, 
including metabolic syndrome, diabetes, atherosclerosis and myocardial infarction (12–14, 
18, 19), with some of the studies including an assessment of oral disease. Furthermore, a 
fundamental basis in consideration of utilization of saliva as a diagnostic fluid is some 
consistency/stability in alterations in levels of targeted analytes between health and disease 
(14, 20, 21). In this regard, various reports have described this type of differentiation in 
health and disease, and stability of selected analytes, similar to those evaluated in the current 
study (22, 23). Kosaka et al. (24) recently demonstrated positive correlations of salivary 
cytokines including IL-6, TNFα and PGE2 with Odds Ratios of 2–3 for carotid 
atherosclerosis. Due to its important cardio-metabolic actions, adiponectin represents a 
biological molecule of interest and is a potential emerging biomarker of disease. 
Furthermore, CRP levels in serum and saliva have been identified related to CVD (25–28). 
Thus, we targeted these two biomolecules in various biological fluids of patients suffering 
myocardial infarction that should enable additional information on their relationship to these 
clinical events and oral health of the individuals.
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MATERIALS and METHODS
Patient Recruitment
The rights of human subjects involved in this study were protected by the institutional 
review board of the research site. In all cases, informed consent was granted prior to sample 
collection. To ensure privacy rights of study participants, all samples were tested in a de-
identified manner.
A cross-sectional clinical study was implemented, and 92 patients were recruited with acute 
myocardial infarction (AMI), along with 111 age- and gender-matched non-AMI controls at 
hospitals of the University of Kentucky and University of Louisville. All AMI patients were 
enrolled within 48 hours of their cardiac event. Patients were classified as STEMI based on 
ECG elevation of ST-segments by −0.1 mV in contiguous leads in patients with ischemic 
symptoms and increased cardiac biomarkers (99th percentile of the upper reference limit for 
troponin I (TnI), cutoff 0.04 ng/mL). Diagnoses of NSTEMI were made for patients with 
ischemic symptoms and ECG changes consistent with ischemia (depression of the ST 
segments or new left bundle branch block), new pathologic Q-waves, or evidence of 
perfusion defects on stress test, and were followed by confirmatory positive TnI test as a 
standard measure of myocardial damage. All study participants were at least 18 years old. 
Exclusion criteria were fever, stroke, immune disorders, use of steroid medications, organ 
complications/failure, and inability to provide saliva. Demographic information was 
obtained (Table 1), medical records reviewed, oral evaluation performed, and biological 
fluids obtained (blood and UWS) from each study participant. Samples were transported on 
ice to a local laboratory, centrifuged, and divided into aliquots. The specimens were 
generally kept on ice for <1 hr., prior to being stored at −80 °C, and analyzed within 3 
months of collection.
As we have described previously, oral health was assessed visually at the bedside to not 
interfere with medical management of the AMI patients or in the dental operatory for 
controls. Oral health was scored as poor, fair, or good based similar to approaches used 
previously (29, 30). Poor was defined as generalized areas of mucosal inflammation, 
multiple broken down teeth, obvious tooth or gum infection or reports loose teeth; Fair was 
defined as may have oral complaints, localized areas of mucosal inflammation, areas of 
visible decay, no obvious tooth or gum infection; and Good was defined as no complaints, 
no obvious mucosal inflammation, no reported loosed teeth or symptoms of disease. 
Additionally, the number of teeth was determined as an estimate of past and existing dental 
disease (31). Informed consent was granted prior to sample collection. To ensure privacy 
rights of study participants, all samples were de-identified and then assayed.
Sample Collection and Processing for Analysis of Serum and Salivary Analytes
Two vacutainer tubes of blood were collected from each subject. One tube was sent to the 
University of Kentucky Chandler Medical Center Hospital CLIA-approved laboratory for 
assessment of serum lipid levels. The second tube was processed for serum collection, 
aliquoted and stored frozen at −80°C. Unstimulated whole expectorated saliva (UWS) 
samples (5 mL) were collected from each subject at baseline and at 4 (+/− 30 min.) hours 
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post-procedure according to a modification in the method described by Navazesh (32). 
Samples were collected into sterile tubes containing a protease inhibitor solution 
(SIGMAFAST, Sigma, St. Louis, MO.), then transported to the laboratory on ice, 
centrifuged, separated into aliquots and stored at −80°C until analyzed.
A Luminex IS-100 instrument was used for multiplexed detection of C-reactive protein 
(CRP) and adiponectin with kits available from Beadlyte Technology (Millipore, St. Charles, 
MO, USA) (13). All samples were analyzed in duplicate. Standards were included on all 
runs and results are reported within the linearity of the assays. The adiponectin assay range 
was 250-0.08 ng/mL with a minimal detectable dose (MDD) of 0.056 ng/mL and the CRP 
assessment was 50-0.016 ng/mL with an MDD of 0.0012 ng/nL. These two host response 
molecules are studied in the context of serum and unstimulated whole saliva for patients 
with acute myocardial infarction (AMI) and compared to age and gender matched non-AMI 
control subjects.
Blood lipid levels were determined using a Beckman UniCel DxC 800 Synchron Clinical 
Systems instrument in the Clinical Laboratory Improvement Amendments (CLIA)-certified 
serum chemistry laboratory of the University of Kentucky Hospital.
Statistical Analysis
Interval level demographic variables were presented as mean and standard deviation (SD) 
and categorical demographic variables as frequencies and percentages. Biomarker levels 
were presented as mean, median and SD. Percentages were compared among groups using 
chi-square statistics. Comparison of means were based on one way ANOVA, two way 
ANOVA or two-sample t-tests depending on the number of groups being compared; each 
biomarker was log transformed in these comparisons. Pearson’s correlations were based on 
log transformed biomarker data. Statistical analyses were performed using the PC SAS 9.2 
(SAS Institute Inc., Cary, NC, USA) with significance determined at p<0.05 level.
RESULTS
Demographics of population
Table 1 shows that the control subjects were slightly younger and more likely to be female, 
but were comparable to AMI patients on percent white race, and percent reporting current 
alcohol use. As expected the NSTEMI and STEMI groups had significantly more tobacco 
users than controls. Table 1 also shows that the AMI and control groups are comparable on 
mean BMI, and triglycerides levels, but that the control group had elevated total cholesterol, 
LDL and HDL levels compared to the AMI group (P<0.004 in each case).
Adiponectin and CRP levels in AMI
Figure 1A depicts the levels of adiponectin and CRP in serum and saliva from the AMI and 
control groups. As might be expected, CRP levels were significantly elevated in both serum 
and saliva of the AMI patients (P<0.0001, in each case) (8). As expected based upon the 
vascular protective effects of adiponectin, significantly increased levels in the serum of 
control group compared to the AMI patients were observed (P=0.0034). In contrast, the 
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adiponectin levels were increased by about 50% in saliva from the AMI patients, although 
this did not reach statistical significance (P = 0.58).
Based on our previous data (13) suggesting variations in levels of selected salivary analytes 
in AMI patients presenting with STEMI compared to NSTEMI coronary events, we 
stratified the AMI patients into these subsets. Here significantly increased levels of CRP in 
both serum and saliva of STEMI and NSTEMI patients compared to controls (P<0.0001 in 
all cases) were observed (Figure 1B). In addition, the STEMI patients showed significantly 
higher CRP concentrations compared to NSTEMI patients (P=0.0035 in both cases). A 
similar overview for serum adiponectin levels showed a stepwise decrease in adiponectin 
levels from control subjects through STEMI patients (P=0.0035, control versus STEMI and 
P=0.082 control versus NTEMI). In contrast, saliva adiponectin levels were not significantly 
different among these three groups (P=0.62).
BMI and lipids related to adiponectin and CRP
Figure 2 explores the relationship between BMI and levels of serum and salivary adiponectin 
and CRP. Serum adiponectin levels were elevated in the controls compared to AMI in BMI 
tertiles 1 and 3, but not tertile 2 (P = 0.0075, 0.013, and 0.83, respectively). In contrast, 
saliva adiponectin did not vary systematically between control and AMI in any tertile, 
although the control levels did decline with tertile. On the other hand, the levels of CRP 
were increased monotonically in AMI compared to control in all tertiles for both serum and 
saliva (P<0.003 in all cases) and in serum appeared to vary by tertile in both groups.
Table 2 summarizes the observed relationships between the serum and salivary analytes, and 
the serum lipid levels. Adiponectin levels in serum and saliva were positively correlated with 
serum HDL and negatively correlated with serum triglyceride levels in the control subjects 
(P<0.04 for each comparison). In the AMI patients, salivary adiponectin levels were 
positively correlated with total cholesterol and LDL levels (P<0.001 in both cases). With 
CRP, significant relationships were not noted in either biological fluid in either of the 
cohorts. Levels of both adiponectin and CRP in the two biological fluids were significantly 
positively correlated in the control subjects (P<0.008 in both cases) and were positively 
correlated for adiponectin in the AMI patients (P=0.008).
Oral health relationship to adiponectin and CRP
Figure 3 summarizes the comparison of oral health in the control subjects and AMI patients. 
The AMI patients had significantly fewer teeth and significantly worse overall oral health 
than the control group (P<0.0001 for each comparison). The relationship of serum and 
salivary adiponectin and CRP with the number of teeth in each patient was examined in the 
context of the severity of oral disease as shown in Figure 4. This data reveals significantly 
increasing levels of serum CRP in AMI subjects with increasing number of teeth. Serum 
CRP levels were significantly elevated in AMI patients compared to controls irrespective of 
the number of teeth present (P<0.03 for each subgroup). Salivary CRP was also increased in 
the AMI versus control subjects in the lowest and highest subgroups (P<0.008 in both cases 
but not the middle subgroup). Figure 4 also depicts adiponectin levels. In serum, control 
levels of adiponectin are elevated for the two subgroups with the most teeth (P<0.02 in both 
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comparisons) while salivary adiponectin levels were elevated in the AMI group compared to 
the controls in only the highest subgroup (P=0.02).
DISCUSSION
The BMI levels were similar in the AMI and control groups, which may be expected, since 
the control patients were selected from family and acquaintances of the patients with the 
cardiac events enlisted into the study. However, the AMI patients had significantly fewer 
teeth and significantly worse oral health than the control group, consistent with some of the 
existing literature supporting worse oral health in patients with cardiovascular diseases and 
the potential linkage of chronic infection and inflammation in the oral cavity contributing to 
systemic risk changes for CVD (33–37).
Consistent with the documented elevation in CRP levels in patients at risk for CVD events 
(9), the levels were significantly elevated in both serum and saliva of the AMI patients. Of 
particular interest, was the observation that even using a control population with a number of 
existing risk factors for CVD, CRP was significantly elevated above the controls in both 
fluids from the patients who had a cardiac event. These findings were even more pronounced 
with levels of CRP in serum and saliva of STEMI and NSTEMI patients compared to 
controls, with STEMI patients showing the greatest levels of CRP. This finding is consistent 
with the STEMI patients generally considered to have a more severe myocardial infarction 
and tissue damage (38). Since the samples were collected within 48 hrs. of the event, we 
cannot determine whether these elevated CRP levels presaged the AMI or if this molecule 
increased rapidly post-ischemia, or both, and is a limitation of this investigation.
Adiponectin is considered to exert anti-inflammatory effects via macrophages through 
suppressing the production of pro-inflammatory cytokines (1) and contributes to a 
significant reduction of the risk of myocardial infarction, even after correction for HDL- and 
LDL-cholesterol and body mass index (BMI) (39). In non-diabetic subjects, levels of 
adiponectin are inversely related to CVD severity (4) and low plasma adiponectin is 
associated with an early onset of coronary heart disease emphasizing that adiponectin is 
influenced by body fat status and associated with CVD (40). Adiponectin has also been 
reported to be negatively correlated with plasma triglycerides and positively correlated with 
HDL (3, 5). The present study demonstrated that adiponectin levels were significantly 
increased in the serum of control versus AMI patients, which might be expected from the 
existing literature. Moreover, the serum adiponectin levels were lowest in the STEMI 
patients, consistent with a lower level of this protective adipokine in patients with the most 
severe cardiac events.
The adiponectin and CRP levels were inversely related within these populations, similar to a 
report by George and coworkers (41) showing a negative relationship of serum adiponectin 
and CRP levels, reflecting an increased risk indicator of cardiovascular disease. Plasma 
adiponectin levels are decreased in obesity (39, 42, 43). We observed lower levels of serum 
adiponectin and higher levels of CRP in both control subjects and the AMI patients related 
to BMI of the individuals. This is consistent with an increased level of obesity coincident 
with decreased systemic adiponectin, which would represent an anti-inflammatory protective 
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factor for CVD in the patients. Moreover, the pro-inflammatory aspects of excess adipose 
tissue would be expected to contribute to adverse levels of CRP in the serum that has been 
demonstrated as a predictive risk indicator for CVD (9, 11, 44). An accompanying 
interesting interpretation of these findings was that this relationship existed in both the 
control subjects and AMI patients. As noted previously, we deliberately selected a control 
population, as not inherently CVD normal, but one that was similar to the AMI patients in 
demographic and clinical features, absent a cardiac event. The results then would imply that 
a number of the “control” patients demonstrated multiple risk markers for a future ischemic 
event.
Some previous studies have identified adiponectin in saliva (45, 46) and provided evidence 
validating the characteristics of the adiponectin biomolecules in saliva (47). Toda et al. (45) 
found a significant correlation between salivary and serum adiponectin in healthy male 
volunteers >43 years of age. A more recent study confirmed this relationship in both 
genders, as well as younger subjects (48). We observed that salivary adiponectin levels 
decreased in the AMI patients with increased BMI. Thus, there appears to be a reflection of 
the host responses to obesity that is reflected in both the serum and saliva of the subjects, 
albeit, the existence of a cardiac event modulates these responses. Nigro et al. (47) recently 
evaluated adiponectin level is saliva related to obesity and show a higher expression of both 
high and low molecular weight forms in saliva from obese patients, suggesting a potential 
for salivary biomarkers in metabolic disorders. Elevated salivary CRP levels (6-fold) and 
decreased adiponectin levels (30%) were noted in obese children (49). Saliva and serum 
adiponectin levels were correlated and plasma adiponectin was decreased with increased 
triglyceride levels and waist circumference in metabolic syndrome patients (50). as well as 
correlations in salivary and serum CRP and adiponectin in postmenopausal women (51).
The adipokines (resistin, visfatin, and adiponectin) were examined in saliva of healthy 
individuals and showed a significant correlation between adiponectin in saliva and serum 
from healthy subjects, but provided no insight into variations in this biomolecule related to 
disease, or risk of disease (48). In the present study, both adiponectin and CRP levels were 
significantly positively correlated in the biological fluids from the control subjects 
suggesting that the salivary levels of the molecules likely are reflecting a direct serum 
contribution to the oral cavity irrespective of the level of oral health or disease. Interestingly, 
this relationship was lost in the AMI patients.
A study identified a substantial increase in periodontitis in AMI patients, associated with 
elevations in serum CRP, but not adiponectin (52). In the PAROKRANK Study 
(Periodontitis and Its Relation to Coronary Artery Disease), in patients with an initial 
myocardial infarct MMP-8 and myeloperoxidase were elevated in non-MI versus MI 
patients and primarily correlated with clinical signs of periodontal inflammation (53). 
Salivary CRP levels have been shown to be correlated with arterial blood pressure, BMI, and 
intima-media thickness, as was MMP-9 in saliva. Lipid inflammatory mediators (LTB4 
PGE2) in saliva were also associated with arterial stiffness (54). Salivary malondialdehyde 
levels (a measure of lipid peroxidation) were elevated in both chronic adult periodontitis and 
acute coronary syndrome patients. These levels also correlated with periodontal clinical 
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parameters and levels of serum CRP and fibrinogen (55). Furthermore, a recent case-control 
study identified significantly elevated salivary CRP levels in the periodontitis group (56).
Significantly increased levels of serum CRP in the control subjects was related to increasing 
numbers of teeth. In contrast, serum CRP levels were significantly elevated in AMI patients 
compared to controls irrespective of the number of teeth present. Control subjects with the 
fewest teeth had the lowest serum adiponectin levels and the AMI group presented a profile 
of adiponectin that was generally unaffected by the number of teeth present. Salivary 
adiponectin levels were generally increased in both controls and AMI patients with 
increasing number of teeth, while salivary CRP was only elevated in AMI patients with the 
greatest number of teeth. These findings indicate a relationship of the inflammatory (CRP) 
and anti-inflammatory (adiponectin) biomolecules with BMI, and an association of these 
levels that relate to tooth number and potentially reflect the level of oral health. Interestingly, 
studies have also demonstrated that oral bacterial stimulation of periodontal cells can induce 
local production of adiponectin (57). Moreover, administration of adiponectin in a murine 
periodontitis model reduced alveolar bone loss, reflecting altered osteoclastogenesis with 
decreased osteoclast numbers (58), thus supporting some relationship between these 
biomolecules and biological processes occurring in the oral cavity.
While a limitation of the study could be perceived to be related to the predominant 
Caucasian distribution of the population, the overall profile of our study group was in the 
range of the 75% U.S. and 90% Kentucky race/ethnicity population base. Moreover, a 
potential confounder in the clinical assessment of the subjects, was the potential that dental 
services were provided immediately preceding entry into the study and could affect these 
measures, as well as the potential that following AMI, general oral hygiene practices could 
be substantially altered leading to a readout of worse oral health. The clinical evaluation of 
the AMI patients was conducted within 48 hrs. of the event, thus, we feel it unlikely that this 
interval would have minimal impact on the tooth numbers and overall oral health 
categorization. Additionally, while it is possible that the control group had a greater number 
of individuals that had received recent dental prophylaxis versus the AMI patients, we 
accessed the control group from the general subject pool of individuals as represented by the 
AMI patients. Thus, we believe it is unlikely that the access to active professional dental 
services significantly impacted the overall oral health evaluation between the two groups, we 
cannot totally eliminate this confounder with the data available. These findings provide 
insight into the interrelationships of a systemic anti-inflammatory and proinflammatory 
biomarker in AMI patients, including documenting difference in levels of these analytes in 
unstimulated whole saliva that could contribute to profiling the biologic risk of individuals 
for cardiac events.
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Figure 1. 
(A) Box plot of levels of adiponectin and CRP in serum and saliva from the AMI and control 
groups. Box represents 25th–75th percentile, horizontal line is median value, and whiskers 
denote range of values in the groups. The asterisk (*) denotes significantly different from 
control group at least at p<0.05. (B) Levels of CRP and adiponectin in serum and saliva of 
STEMI and NSTEMI patients compared to controls. The asterisk (*) denotes significantly 
different from disease groups at least at p<0.05, and cross (†) denotes significant difference 
in levels in STEMI vs. NSTEMI at p<0.01.
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Figure 2. 
Levels of serum and salivary adiponectin and CRP in both control subjects and AMI patients 
related to tertiles of BMI of the individuals. The bars denote group means and the vertical 
brackets enclose 1 SD. The asterisk denotes levels in control significantly different from 
AMI at least at p<0.05.
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Figure 3. 
summarizes the comparison of oral health in the control subjects and AMI patients, both as 
number of teeth and oral health categorization. The asterisk denotes significant difference at 
p<0.05.
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Figure 4. 
Levels of serum and salivary CRP and adiponectin in control and AMI subjects with 
increasing numbers of teeth. The bars denote group means and the vertical brackets enclose 
1 SD. The asterisk (*) denotes significantly different from control group at least at p<0.05. 
The cross (†) denotes significantly different from other AMI tooth categories at p<0.01.
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Table 1
Demographics, BMI and serum lipid levels in the control and AMI subjects.
AMI
Control NSTEMI STEMI TOTAL
N 111 34 58 92
Age (yrs.) 48.6 ± 8.9 53.1 ± 11.7 54.8 ± 12.0 54.2 ± 11.9
Female (%) 55.9 29.4 29.3 29.3
White (%) 84.7 82.4 86.2 84.8
Current Tobacco Use (%) 22.5 58.8* 77.6* 70.7*
Current Alcohol Use (%) 26.1 26.5 32.8 30.4
Total Cholesterol 189.6 ± 40.1* 148.1 ± 65.9
HDL 46.8 ± 13.1* 39.8 ± 35.4
LDL 116.5 ± 29.8* 93.3 ± 39.2
Triglycerides 151.1 ± 87.6 168.8 ± 102.5
BMI 28.1 ± 5.6 29.0 ± 6.3
*
Denotes significantly different from control at p<0.05.
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